Federal regulators have cleared a new targeted drug for advanced breast cancer, giving patients with a common form of the disease an option built on the results of a large clinical trial. The approval rests on a study called VIKTORIA-1, which tested the medication in people whose cancer is hormone-receptor positive and had progressed or spread, and it notably extends a treatment approach to a group of patients who previously fell outside such options.
Breast cancer that has advanced or metastasized remains the form that is hardest to treat, and much of the recent progress has come from drugs aimed at the specific molecular machinery that fuels tumor growth. The newly approved medication follows that pattern, targeting a signaling pathway that cancers frequently hijack — and doing so in a way that broadens who is eligible to benefit.
Which patients the approval covers
The drug is gedatolisib, sold under the brand name Revtorpyk and made by the biotech firm Celcuity. According to the regulator, the Food and Drug Administration approved gedatolisib in combination with the anti-hormone drug fulvestrant, with or without the targeted inhibitor palbociclib, for hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer. It is meant to be used alongside those existing therapies rather than on its own.
A key detail is who qualifies. The approval covers patients whose tumors do not carry a mutation in a gene called PIK3CA — the so-called wild-type form. That matters because several earlier targeted drugs for this pathway were limited to patients who did have that mutation, leaving a large share of people without a comparable option. By covering the wild-type group, the new approval reaches patients who had been excluded from that class of treatment.
How gedatolisib attacks the tumor’s signaling
Gedatolisib works by hitting a growth-signaling pathway that many breast cancers rely on to keep dividing and to resist treatment. It is described as a multi-targeted inhibitor, meaning it blocks several points along that pathway rather than a single node — an approach intended to make it harder for the cancer to find a way around the drug. Cancers often develop resistance by rerouting around a blocked step, so shutting down multiple points at once is a strategy to close off those escape routes.
Pairing the drug with fulvestrant, which lowers the tumor’s exposure to estrogen, and optionally with palbociclib, which interrupts the cell’s division cycle, is designed to attack the cancer on more than one front. That combination logic is central to modern treatment of hormone-driven breast cancer, where stacking mechanisms has repeatedly outperformed single agents in delaying the disease’s return.
What the VIKTORIA-1 trial showed
The evidence behind the approval comes from a randomized study. As reported on the VIKTORIA-1 trial, which enrolled 392 patients, those receiving the three-drug combination had a median progression-free survival of 9.3 months and those on the two-drug regimen 7.4 months, compared with just 2.0 months for patients on fulvestrant alone. Progression-free survival measures how long patients live without their cancer worsening, so the gap reflects a meaningful delay in the disease advancing.
The contrast with the fulvestrant-only group — 9.3 or 7.4 months versus 2.0 — is the core of the case for the drug, showing that adding gedatolisib substantially lengthened the time before the cancer progressed. The trial was led by a breast cancer specialist at Fred Hutch, and the results were the basis on which regulators judged the benefit worth the risks. As with any such figure, these are median values within a trial population rather than promises for any individual patient.
Why widening eligibility matters
The significance of the approval is as much about reach as about the survival numbers. The research center whose scientist led the trial framed the drug as newly available to a large share of metastatic breast cancer patients who had lacked a comparable targeted option, because it can be used in those without the PIK3CA mutation. In a disease where prior drugs of this type were gated behind a specific mutation, opening the door to the wild-type majority expands the pool of patients who might benefit.
That broadening does not make the drug a cure or free of trade-offs. Drugs that block this signaling pathway can carry side effects that require monitoring, and progression-free survival gains measured in months, while genuinely valuable in advanced disease, are not the same as long-term remission. Oncologists will weigh the benefit against tolerability for each patient, and real-world use will refine the picture the trial established.
Still, for people facing hormone-receptor-positive advanced breast cancer without the mutation that unlocked earlier targeted drugs, the approval adds a concrete new tool. Built on a trial that showed a clear delay in the cancer’s progression and cleared by regulators for both locally advanced and metastatic disease, gedatolisib gives clinicians another way to slow a cancer that has proven difficult to hold back.
This article was researched and written with the assistance of AI and reviewed by an editor prior to publication.
More from Morning Overview
